The neuromodulation of the intestinal immune system and its relevance in inflammatory bowel disease

Frontiers in Immunology

Volumn 6, Issue NOV, 2015, Pages

  Di Giovangiulio, Martina ^a   Verheijden, Simon ^a   Bosmans, Goele ^a   Stakenborg, Nathalie ^a   Boeckxstaens, Guy E ^a   Matteoli, Gianluca ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Inflammatory bowel disease; Intestinal immune system; Neuropeptide; Oral tolerance; Parasympathetic system; Peptidergic pathway; Sympathetic system

Indexed keywords

BUNGAROTOXIN RECEPTOR; CALCITONIN GENE RELATED PEPTIDE; CHOLINE ACETYLTRANSFERASE; CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR; NEUROPEPTIDE Y; NITRIC OXIDE; OXIDOPAMINE; PROTEIN KINASE C; RETINOIC ACID; SEROTONIN; SEROTONIN RECEPTOR; SUBSTANCE P; THYMIC STROMAL LYMPHOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; VASOACTIVE INTESTINAL POLYPEPTIDE;

CHOLINERGIC SYSTEM; DENDRITIC CELL; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY BOWEL DISEASE; INTESTINAL IMMUNE SYSTEM; MACROPHAGE; MESENTERY LYMPH NODE; MYENTERIC PLEXUS; NERVE CELL MEMBRANE POTENTIAL; NEUROMODULATION; ONCOGENE C FOS; POSTOPERATIVE ILEUS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYMPATHETIC TONE;

EID: 84949568948     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00590     Document Type: Review

References (191)

1. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol (2009) 9(11):799-809. doi: 10.1038/nri2653.
2. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol (2003) 3(4):331-41. doi:10.1038/nri1057.
3. Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol (2012) 5(3):232-9. doi:10.1038/mi.2012.4.
4. Rescigno M. Dendritic cell-epithelial cell crosstalk in the gut. Immunol Rev (2014) 260(1):118-28. doi:10.1111/imr.12181.
5. Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science (2013) 342(6157):447-53. doi:10.1126/science.1237910.
6. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev (2011) 241(1):241-59. doi:10.1111/j.1600-065X.2011.01017.x.
7. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol (2004) 5(6):575-81. doi:10.1038/ni1078.
8. Franco R, Pacheco R, Lluis C, Ahern GP, O'Connell PJ. The emergence of neurotransmitters as immune modulators. Trends Immunol (2007) 28(9):400-7. doi:10.1016/j.it.2007.07.005.
9. Tracey KJ. Reflex control of immunity. Nat Rev Immunol (2009) 9(6):418-28. doi:10.1038/nri2566.
10. Koopman FA, Stoof SP, Straub RH, Van Maanen MA, Vervoordeldonk MJ, Tak PP. Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis. Mol Med (2011) 17(9-10):937-48. doi:10.2119/molmed.2011.00065.
11. Moris G. Inflammatory bowel disease: an increased risk factor for neurologic complications. World J Gastroenterol (2014) 20(5):1228-37. doi:10.3748/wjg.v20.i5.1228.
12. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci (2011) 12(8):453-66. doi:10.1038/nrn3071.
13. Costa M, Brookes SJ, Hennig GW. Anatomy and physiology of the enteric nervous system. Gut (2000) 47(Suppl 4):iv15-9. doi:10.1136/gut.47.suppl_4.iv1.
14. Goyal RK, Hirano I. The enteric nervous system. N Engl J Med (1996) 334(17):1106-15. doi:10.1056/NEJM199604253341707.
15. Lake JI, Heuckeroth RO. Enteric nervous system development: migration, differentiation, and disease. Am J Physiol Gastrointest Liver Physiol (2013) 305(1):G1-24. doi:10.1152/ajpgi.00452.2012.
16. Xue L, Farrugia G, Miller SM, Ferris CD, Snyder SH, Szurszewski JH. Carbon monoxide and nitric oxide as coneurotransmitters in the enteric nervous system: evidence from genomic deletion of biosynthetic enzymes. Proc Natl Acad Sci U S A (2000) 97(4):1851-5. doi:10.1073/pnas.97.4.1851.
17. Bult H, Boeckxstaens GE, Pelckmans PA, Jordaens FH, Van Maercke YM, Herman AG. Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter. Nature (1990) 345(6273):346-7. doi:10.1038/345346a0.
18. Levite M. Nerve-driven immunity. The direct effects of neurotransmitters on T-cell function. Ann N Y Acad Sci (2000) 917:307-21. doi:10.1111/j.1749-6632.2000.tb05397.x.
19. Willemze RA, Luyer MD, Buurman WA, de Jonge WJ. Neural reflex pathways in intestinal inflammation: hypotheses to viable therapy. Nat Rev Gastroenterol Hepatol (2015) 12(6):353-62. doi:10.1038/nrgastro.2015.56.
20. Cailotto C, Costes LM, van der Vilet J, van Bree SH, van Heerikhuize JJ, Buijs RM, et al. Neuroanatomical evidence demonstrating the existence of the vagal anti-inflammatory reflex in the intestine. Neurogastroenterol Motil (2011) 24(2):191-200. doi:10.1111/j.1365-2982.2011.01824.x.
21. Tracey KJ. The inflammatory reflex. Nature (2002) 420(6917):853-9. doi:10.1038/nature01321.
22. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 405(6785):458-62. doi:10.1038/35013070.
23. Rosas-Ballina M, Ochani M, Parrish WR, Ochani K, Harris YT, Huston JM, et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A (2008) 105(31):11008-13. doi:10.1073/pnas.0803237105.
24. Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin X, et al. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med (2007) 35(4):1139-44. doi:10.1097/01.CCM.0000259381.56526.96.
25. Rosas-Ballina M, Olofsson PS, Ochani M, Valdés-Ferrer SI, Levine YA, Reardon C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science (2011) 334(6052):98-101. doi:10.1126/science.1209985.
26. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature (2003) 421(6921):384-8. doi:10.1038/nature01339.
27. Olofsson PS, Rosas-Ballina M, Levine YA, Tracey KJ. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol Rev (2012) 248(1):188-204. doi:10.1111/j.1600-065X.2012.01138.x.
28. Berthoud HR, Jedrzejewska A, Powley TL. Simultaneous labeling of vagal innervation of the gut and afferent projections from the visceral forebrain with dil injected into the dorsal vagal complex in the rat. J Comp Neurol (1990) 301(1):65-79. doi:10.1002/cne.903010107.
29. de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol (2005) 6(8):844-51. doi:10.1038/ni1229.
30. The F, Cailotto C, van der Vliet J, de Jonge WJ, Bennink RJ, Buijs RM, et al. Central activation of the cholinergic anti-inflammatory pathway reduces surgical inflammation in experimental post-operative ileus. Br J Pharmacol (2011) 163(5):1007-16. doi:10.1111/j.1476-5381.2011.01296.x.
31. Matteoli G, Gomez-Pinilla PJ, Nemethova A, Di Giovangiulio M, Cailotto C, van Bree SH, et al. A distinct vagal anti-inflammatory pathway modulates intestinal muscularis resident macrophages independent of the spleen. Gut (2014) 63(6):938-48. doi:10.1136/gutjnl-2013-304676.
32. Olofsson PS, Katz DA, Rosas-Ballina M, Levine YA, Ochani M, Valdés-Ferrer SI, et al. alpha7nAChR expression in bone-marrow derived non T cells is required for the inflammatory reflex. Mol Med (2011) 18:539-43. doi:10.2119/molmed.2011.00405.
33. Cailotto C, Gomez-Pinilla PJ, Costes LM, van der Vliet J, Di Giovangiulio M, Némethova A, et al. Neuro-anatomical evidence indicating indirect modulation of macrophages by vagal efferents in the intestine but not in the spleen. PLoS One (2014) 9(1):e87785. doi:10.1371/journal.pone.0087785.
34. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, Verdu EF, Collins SM. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology (2006) 131(4):1122-30. doi:10.1053/j.gastro.2006.08.016.
35. Bai A, Guo Y, Lu N. The effect of the cholinergic anti-inflammatory pathway on experimental colitis. Scand J Immunol (2007) 66(5):538-45. doi:10.1111/j.1365-3083.2007.02011.x.
36. Ghia JE, Blennerhassett P, Collins SM. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J Clin Invest (2008) 118(6):2209-18. doi:10.1172/JCI32849.
37. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology (2009) 136(7):2280-8. doi:10.1053/j.gastro.2009.02.069.
38. O'Mahony C, van der Kleij H, Bienenstock J, Shanahan F, O'Mahony L. Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. Am J Physiol Regul Integr Comp Physiol (2009) 297(4):R1118-26. doi:10.1152/ajpregu.90904.2008.
39. Snoek SA, Verstege MI, van der Zanden EP, Deeks N, Bulmer DC, Skynner M, et al. Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br J Pharmacol (2010) 160(2):322-33. doi:10.1111/j.1476-5381.2010.00699.x.
40. Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs (1996) 5(19):1195-202. doi:10.12968/bjon.1996.5.19.1195.
41. Wolf JM, Lashner BA. Inflammatory bowel disease: sorting out the treatment options. Cleve Clin J Med (2002) 69(8):621-31. doi:10.3949/ccjm.69.8.621.
42. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis (2004) 10(6):848-59. doi:10.1097/00054725-200411000-00019.
43. Hilsden RJ, Hodgins DC, Timmer A, Sutherland LR. Helping patients with Crohn's disease quit smoking. Am J Gastroenterol (2000) 95(2):352-8. doi:10.1016/S0002-9270(99)00848-5.
44. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol (2004) 18(3):481-96. doi:10.1016/j.bpg.2003.12.003.
45. Mahid SS, Minor KS, Stevens PL, Galandiuk S. The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci (2007) 52(11):2897-903. doi:10.1007/s10620-006-9624-0.
46. Galitovskiy V, Qian J, Chernyavsky AI, Marchenko S, Gindi V, Edwards RA, et al. Cytokine-induced alterations of alpha7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17-versus Th2-mediated colitis. J Immunol (2011) 187(5):2677-87. doi:10.4049/jimmunol.1002711.
47. Rubio A, Pellissier S, Picot A, Dantzer C, Bonaz B. The link between negative affect, vagal tone, and visceral sensitivity in quiescent Crohn's disease. Neurogastroenterol Motil (2014) 26(8):1200-3. doi:10.1111/nmo.12373.
48. Jerndal P, Ringström G, Agerforz P, Karpefors M, Akkermans LM, Bayati A, et al. Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil (2010) 22(6):646-e179. doi:10.1111/j.1365-2982.2010.01493.x.
49. Clarencon D, Pellissier S, Sinniger V, Kibleur A, Hoffman D, Vercueil L, et al. Long term effects of low frequency (10 Hz) vagus nerve stimulation on EEG and heart rate variability in Crohn's disease: a case report. Brain Stimul (2014) 7(6):914-6. doi:10.1016/j.brs.2014.08.001.
50. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology (2013) 144(1):36-49. doi:10.1053/j.gastro.2012.10.003.
51. Straub RH, Wiest R, Strauch UG, Härle P, Schölmerich J. The role of the sympathetic nervous system in intestinal inflammation. Gut (2006) 55(11):1640-9. doi:10.1136/gut.2006.091322.
52. Bellinger DL, Lorton D, Felten SY, Felten DL. Innervation of lymphoid organs and implications in development, aging, and autoimmunity. Int J Immunopharmacol (1992) 14(3):329-44. doi:10.1016/0192-0561(92)90162-E.
53. Felten DL, Felten SY, Carlson SL, Olschowka JA, Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol (1985) 135(2 Suppl):755s-65s.
54. Abrass CK, O'Connor SW, Scarpace PJ, Abrass IB. Characterization of the beta-adrenergic receptor of the rat peritoneal macrophage. J Immunol (1985) 135(2):1338-41.
55. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol (1997) 158(9):4200-10.
56. Straub RH. Complexity of the bi-directional neuroimmune junction in the spleen. Trends Pharmacol Sci (2004) 25(12):640-6. doi:10.1016/j.tips.2004.10.007.
57. Bergquist J, Tarkowski A, Ekman R, Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci U S A (1994) 91(26):12912-6. doi:10.1073/pnas.91.26.12912.
58. Cosentino M, Marino F, Bombelli R, Ferrari M, Rasini E, Lecchini S, et al. Stimulation with phytohaemagglutinin induces the synthesis of catecholamines in human peripheral blood mononuclear cells: role of protein kinase C and contribution of intracellular calcium. J Neuroimmunol (2002) 125(1-2):125-33. doi:10.1016/S0165-5728(02)00019-X.
59. Dorban G, Defaweux V, Demonceau C, Flandroy S, Van Lerberghe PB, Falisse-Poirrier N, et al. Interaction between dendritic cells and nerve fibres in lymphoid organs after oral scrapie exposure. Virchows Arch (2007) 451(6):1057-65. doi:10.1007/s00428-007-0476-6.
60. Manni M, Granstein RD, Maestroni G. beta2-Adrenergic agonists bias TLR-2 and NOD2 activated dendritic cells towards inducing an IL-17 immune response. Cytokine (2011) 55(3):380-6. doi:10.1016/j.cyto.2011.05.013.
61. Yanagawa Y, Matsumoto M, Togashi H. Enhanced dendritic cell antigen uptake via alpha2 adrenoceptor-mediated PI3K activation following brief exposure to noradrenaline. J Immunol (2010) 185(10):5762-8. doi:10.4049/jimmunol.1001899.
62. Nijhuis LE, Olivier BJ, Dhawan S, Hilbers FW, Boon L, Wolkers MC, et al. Adrenergic beta2 receptor activation stimulates anti-inflammatory properties of dendritic cells in vitro. PLoS One (2014) 9(1):e85086. doi:10.1371/journal.pone.0085086.
63. Maestroni GJ, Mazzola P. Langerhans cells beta 2-adrenoceptors: role in migration, cytokine production, Th priming and contact hypersensitivity. J Neuroimmunol (2003) 144(1-2):91-9. doi:10.1016/j.jneuroim.2003.08.039.
64. Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest (1997) 100(6):1513-9. doi:10.1172/JCI119674.
65. Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J Leukoc Biol (2006) 79(6):1093-104. doi:10.1189/jlb.1105625.
66. Gonzalez-Ariki S, Husband AJ. The role of sympathetic innervation of the gut in regulating mucosal immune responses. Brain Behav Immun (1998) 12(1):53-63. doi:10.1006/brbi.1997.0509.
67. Kohm AP, Sanders VM. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev (2001) 53(4):487-525.
68. Jacobson K, McHugh K, Collins SM. The mechanism of altered neural function in a rat model of acute colitis. Gastroenterology (1997) 112(1):156-62. doi:10.1016/S0016-5085(97)70230-0.
69. Motagally MA, Neshat S, Lomax AE. Inhibition of sympathetic N-type voltage-gated Ca2+ current underlies the reduction in norepinephrine release during colitis. Am J Physiol Gastrointest Liver Physiol (2009) 296(5):G1077-84. doi:10.1152/ajpgi.00006.2009.
70. Straub RH, Grum F, Strauch U, Capellino S, Bataille F, Bleich A, et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut (2008) 57(7):911-21. doi:10.1136/gut.2007.125401.
71. Härle P, Möbius D, Carr DJ, Schölmerich J, Straub RH. An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum (2005) 52(4):1305-13. doi:10.1002/art.20987.
72. Vasina V, Abu-Gharbieh E, Barbara G, de Giorgio R, Colucci R, Blandizzi C, et al. The beta3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterol Motil (2008) 20(9):1030-41. doi:10.1111/j.1365-2982.2008.01138.x.
73. Cellek S, Thangiah R, Bassil AK, Campbell CA, Gray KM, Stretton JL, et al. Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology (2007) 133(1):175-83. doi:10.1053/j.gastro.2007.05.009.
74. Bai A, Lu N, Guo Y, Chen J, Liu Z. Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis. Clin Exp Immunol (2009) 156(2):353-62. doi:10.1111/j.1365-2249.2009.03894.x.
75. Boissé L, Chisholm SP, Lukewich MK, Lomax AE. Clinical and experimental evidence of sympathetic neural dysfunction during inflammatory bowel disease. Clin Exp Pharmacol Physiol (2009) 36(10):1026-33. doi:10.1111/j.1440-1681.2009.05242.x.
76. Magro F, Vieira-Coelho MA, Fraga S, Serrão MP, Veloso FT, Ribeiro T, et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci (2002) 47(1):216-24. doi:10.1023/A:1013256629600.
77. Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol (1992) 87(2):176-81.
78. Bueno L, Fioramonti J, Ruckebusch Y. Postoperative intestinal motility in dogs and sheep. Am J Dig Dis (1978) 23(8):682-9. doi:10.1007/BF01072352.
79. Furlan R, Ardizzone S, Palazzolo L, Rimoldi A, Perego F, Barbic F, et al. Sympathetic overactivity in active ulcerative colitis: effects of clonidine. Am J Physiol Regul Integr Comp Physiol (2006) 290(1):R224-32. doi:10.1152/ajpregu.00442.2005.
80. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev (2004) 56(2):249-90. doi:10.1124/pr.56.2.7.
81. Lelievre V, Favrais G, Abad C, Adle-Biassette H, Lu Y, Germano PM, et al. Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides (2007) 28(9):1688-99. doi:10.1016/j.peptides.2007.05.006.
82. Rouyer-Fessard C, Augeron C, Grasset E, Maoret JJ, Laboisse CL, Laburthe M. VIP receptors and control of short circuit current in the human intestinal clonal cell line Cl.19A. Experientia (1989) 45(11-12):1102-5. doi:10.1007/BF01950169.
83. Delgado M, Reduta A, Sharma V, Ganea D. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. J Leukoc Biol (2004) 75(6):1122-30. doi:10.1189/jlb.1203626.
84. Håkanson R, Chen D, Lindström E, Bernsand M, Norlén P. Control of secretion from rat stomach ECL cells in situ and in primary culture. Scand J Clin Lab Invest Suppl (2001) 234:53-60. doi:10.1080/003655101753352059.
85. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des (2001) 7(2):89-111. doi:10.2174/1381612013398374.
86. Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, et al. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann N Y Acad Sci (2006) 1070:129-34. doi:10.1196/annals.1317.001.
87. Foster N, Lea SR, Preshaw PM, Taylor JJ. Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol (2007) 81(4):893-903. doi:10.1189/jlb.0206086.
88. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol (2005) 175(11):7311-24. doi:10.4049/jimmunol.175.11.7311.
89. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood (2006) 107(9):3632-8. doi:10.1182/blood-2005-11-4497.
90. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J (2002) 16(13):1844-6. doi:10.1096/fj.02-0248fje.
91. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, et al. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci U S A (2001) 98(24):13854-9. doi:10.1073/pnas.241503798.
92. Delgado M. VIP: a very important peptide in T helper differentiation. Trends Immunol (2003) 24(5):221-4. doi:10.1016/S1471-4906(03)00069-3.
93. Abad C, Cheung-Lau G, Coûté-Monvoisin AC, Waschek JA. Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis. Neuroimmunomodulation (2015) 22(3):203-12. doi:10.1159/000364912.
94. O'Morain C, Bishop AE, McGregor GP, Levi AJ, Bloom SR, Polak JM, et al. Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. Gut (1984) 25(1):57-61. doi:10.1136/gut.25.1.57.
95. Todorovic V, Janic B, Koko V, Micev M, Nikolic JA, Ratkovic M, et al. Colonic vasoactive intestinal polypeptide (VIP) in ulcerative colitis-a radioimmunoassay and immunohistochemical study. Hepatogastroenterology (1996) 43(9):483-8.
96. Surrenti C, Renzi D, Garcea MR, Surrenti E, Salvadori G. Colonic vasoactive intestinal polypeptide in ulcerative colitis. J Physiol Paris (1993) 87(5):307-11. doi:10.1016/0928-4257(93)90037-T.
97. Larhammar D, Ericsson A, Persson H. Structure and expression of the rat neuropeptide Y gene. Proc Natl Acad Sci U S A (1987) 84(7):2068-72. doi:10.1073/pnas.84.7.2068.
98. Silva AP, Cavadas C, Grouzmann E. Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin Chim Acta (2002) 326(1-2):3-25. doi:10.1016/S0009-8981(02)00301-7.
99. Blomqvist AG, Söderberg C, Lundell I, Milner RJ, Larhammar D. Strong evolutionary conservation of neuropeptide Y: sequences of chicken, goldfish, and Torpedo marmorata DNA clones. Proc Natl Acad Sci U S A (1992) 89(6):2350-4. doi:10.1073/pnas.89.6.2350.
100. Dimitrijevic M, Stanojevic S. The intriguing mission of neuropeptide Y in the immune system. Amino Acids (2013) 45(1):41-53. doi:10.1007/s00726-011-1185-7.
101. Wheway J, Herzog H, Mackay F. The Y1 receptor for NPY: a key modulator of the adaptive immune system. Peptides (2007) 28(2):453-8. doi:10.1016/j.peptides.2006.09.030.
102. Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, Herzog H, et al. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med (2005) 202(11):1527-38. doi:10.1084/jem.20051971.
103. Mitić K, Stanojević S, Kuštrimović N, Vujić V, Dimitrijević M. Neuropeptide Y modulates functions of inflammatory cells in the rat: distinct role for Y1, Y2 and Y5 receptors. Peptides (2011) 32(8):1626-33. doi:10.1016/j.peptides.2011.06.007.
104. Fägerstam JP, Whiss PA, Ström M, Andersson RG. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm Res (2000) 49(9):466-72. doi:10.1007/s000110050618.
105. Schwarz H, Villiger PM, von Kempis J, Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol (1994) 51(1):53-61. doi:10.1016/0165-5728(94)90128-7.
106. Chandrasekharan B, Bala V, Kolachala VL, Vijay-Kumar M, Jones D, Gewirtz AT, et al. Targeted deletion of neuropeptide Y (NPY) modulates experimental colitis. PLoS One (2008) 3(10):e3304. doi:10.1371/journal.pone.0003304.
107. Painsipp E, Herzog H, Sperk G, Holzer P. Sex-dependent control of murine emotional-affective behaviour in health and colitis by peptide YY and neuropeptide Y. Br J Pharmacol (2011) 163(6):1302-14. doi:10.1111/j.1476-5381.2011.01326.x.
108. Hassani H, Lucas G, Rozell B, Ernfors P. Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling. Am J Physiol Gastrointest Liver Physiol (2005) 288(3):G550-6. doi:10.1152/ajpgi.00182.2004.
109. Baticic L, Detel D, Kucic N, Buljevic S, Pugel EP, Varljen J. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. J Cell Biochem (2011) 112(11):3322-33. doi:10.1002/jcb.23261.
110. Hagner S, Knauer J, Haberberger R, Göke B, Voigt K, McGregor GP. Calcitonin receptor-like receptor is expressed on gastrointestinal immune cells. Digestion (2002) 66(4):197-203. doi:10.1159/000068365.
111. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med (2004) 32(8):1715-21. doi:10.1097/01.CCM.0000134404.63292.71.
112. Tóth BI, Benko S, Szöllosi AG, Kovács L, Rajnavölgyi E, Bíró T. Transient receptor potential vanilloid-1 signaling inhibits differentiation and activation of human dendritic cells. FEBS Lett (2009) 583(10):1619-24. doi:10.1016/j.febslet.2009.04.031.
113. Zhao JF, Ching LC, Kou YR, Lin SJ, Wei J, Shyue SK, et al. Activation of TRPV1 prevents OxLDL-induced lipid accumulation and TNF-alpha-induced inflammation in macrophages: role of liver X receptor alpha. Mediators Inflamm (2013) 2013:925171. doi:10.1155/2013/925171.
114. Fernandez S, Knopf MA, Bjork SK, McGillis JP. Bone marrow-derived macrophages express functional CGRP receptors and respond to CGRP by increasing transcription of c-fos and IL-6 mRNA. Cell Immunol (2001) 209(2):140-8. doi:10.1006/cimm.2001.1795.
115. Matsumoto K, Hosoya T, Tashima K, Namiki T, Murayama T, Horie S. Distribution of transient receptor potential vanilloid 1 channel-expressing nerve fibers in mouse rectal and colonic enteric nervous system: relationship to peptidergic and nitrergic neurons. Neuroscience (2011) 172:518-34. doi:10.1016/j.neuroscience.2010.10.024.
116. Eysselein VE, Reinshagen M, Patel A, Davis W, Nast C, Sternini C. Calcitonin gene-related peptide in inflammatory bowel disease and experimentally induced colitis. Ann N Y Acad Sci (1992) 657:319-27. doi:10.1111/j.1749-6632.1992.tb22779.x.
117. Mantyh PW, Catton MD, Boehmer CG, Welton ML, Passaro EP Jr, Maggio JE, et al. Receptors for sensory neuropeptides in human inflammatory diseases: implications for the effector role of sensory neurons. Peptides (1989) 10(3):627-45. doi:10.1016/0196-9781(89)90154-X.
118. Holzer P. Implications of tachykinins and calcitonin gene-related peptide in inflammatory bowel disease. Digestion (1998) 59(4):269-83. doi:10.1159/000007504.
119. Mulderry PK, Ghatei MA, Spokes RA, Jones PM, Pierson AM, Hamid QA, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience (1988) 25(1):195-205. doi:10.1016/0306-4522(88)90018-8.
120. Holzmann B. Modulation of immune responses by the neuropeptide CGRP. Amino Acids (2013) 45(1):1-7. doi:10.1007/s00726-011-1161-2.
121. MuffR, Born W, Lutz TA, Fischer JA. Biological importance of the peptides of the calcitonin family as revealed by disruption and transfer of corresponding genes. Peptides (2004) 25(11):2027-38. doi:10.1016/j.peptides.2004.08.007.
122. Engel MA, Khalil M, Mueller-Tribbensee SM, Becker C, Neuhuber WL, Neurath MF, et al. The proximodistal aggravation of colitis depends on substance P released from TRPV1-expressing sensory neurons. J Gastroenterol (2012) 47(3):256-65. doi:10.1007/s00535-011-0495-6.
123. Mazelin L, Theodorou V, More J, Fioramonti J, Bueno L. Protective role of vagal afferents in experimentally-induced colitis in rats. J Auton Nerv Syst (1998) 73(1):38-45. doi:10.1016/S0165-1838(98)00113-1.
124. Shepherd AJ, Downing JE, Miyan JA. Without nerves, immunology remains incomplete-in vivo veritas. Immunology (2005) 116(2):145-63. doi:10.1111/j.1365-2567.2005.02223.x.
125. Goode T, O'Connell J, Anton P, Wong H, Reeve J, O'Sullivan GC, et al. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut (2000) 47(3):387-96. doi:10.1136/gut.47.3.387.
126. Walsh JA, Sootkoos AC. Impact of Souder v. Brennan on the profoundly and severely retarded. J Psychiatr Nurs Ment Health Serv (1976) 14(2):14-8.
127. Pelayo JC, Veldhuis NA, Eriksson EM, Bunnett NW, Poole DP. Localisation and activation of the neurokinin 1 receptor in the enteric nervous system of the mouse distal colon. Cell Tissue Res (2014) 356(2):319-32. doi:10.1007/s00441-014-1822-z.
128. Mule F, Amato A, Serio R. Role for NK(1) and NK(2) receptors in the motor activity in mouse colon. Eur J Pharmacol (2007) 570(1-3):196-202. doi:10.1016/j.ejphar.2007.05.036.
129. Goode T, O'Connell J, Ho WZ, O'Sullivan GC, Collins JK, Douglas SD, et al. Differential expression of neurokinin-1 receptor by human mucosal and peripheral lymphoid cells. Clin Diagn Lab Immunol (2000) 7(3):371-6. doi:10.1128/CDLI.7.3.371-376.2000.
130. Smith VC, Sagot MA, Couraud JY, Buchan AM. Localization of the neurokinin 1 (NK-1) receptor in the human antrum and duodenum. Neurosci Lett (1998) 253(1):49-52. doi:10.1016/S0304-3940(98)00618-1.
131. Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol (1993) 88(6):908-13.
132. Goldin E, Karmeli F, Selinger Z, Rachmilewitz D. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci (1989) 34(5):754-7. doi:10.1007/BF01540348.
133. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol (1997) 159(11):5654-60.
134. Raap M, Rudrich U, Stander S, Gehring M, Kapp A, Raap U. Substance P activates human eosinophils. Exp Dermatol (2015) 24(7):557-9. doi:10.1111/exd.12717.
135. Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol (1998) 86(1):80-6. doi:10.1016/S0165-5728(98)00025-3.
136. Castagliuolo I, Keates AC, Qiu B, Kelly CP, Nikulasson S, Leeman SE, et al. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci U S A (1997) 94(9):4788-93. doi:10.1073/pnas.94.9.4788.
137. Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J, et al. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol (2000) 279(6):G1298-306.
138. Sturiale S, Barbara G, Qiu B, Figini M, Geppetti P, Gerard N, et al. Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci U S A (1999) 96(20):11653-8. doi:10.1073/pnas.96.20.11653.
139. Kimura M, Masuda T, Hiwatashi N, Toyota T, Nagura H. Changes in neuropeptide-containing nerves in human colonic mucosa with inflammatory bowel disease. Pathol Int (1994) 44(8):624-34. doi:10.1111/j.1440-1827.1994.tb01723.x.
140. Castagliuolo I, Morteau O, Keates AC, Valenick L, Wang CC, Zacks J, et al. Protective effects of neurokinin-1 receptor during colitis in mice: role of the epidermal growth factor receptor. Br J Pharmacol (2002) 136(2):271-9. doi:10.1038/sj.bjp.0704697.
141. Koon HW, Zhao D, Na X, Moyer MP, Pothoulakis C. Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem (2004) 279(44):45519-27. doi:10.1074/jbc. M408523200.
142. Koch TR, Carney JA, Go VL. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci (1987) 32(4):369-76. doi:10.1007/BF01296290.
143. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology (2007) 132(1):397-414. doi:10.1053/j.gastro.2006.11.002.
144. Gershon MD. Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Trans Am Clin Climatol Assoc (2012) 123:268-80.
145. Li Z, Chalazonitis A, Huang YY, Mann JJ, Margolis KG, Yang QM, et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. J Neurosci (2011) 31(24):8998-9009. doi:10.1523/JNEUROSCI.6684-10.2011.
146. Kim JJ, Bridle BW, Ghia JE, Wang H, Syed SN, Manocha MM, et al. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol (2013) 190(9):4795-804. doi:10.4049/jimmunol.1201887.
147. Ghia JE, Li N, Wang H, Collins M, Deng Y, El-Sharkawy RT, et al. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology (2009) 137(5):1649-60. doi:10.1053/j.gastro.2009.08.041.
148. Haub S, Ritze Y, Bergheim I, Pabst O, Gershon MD, BischoffSC. Enhancement of intestinal inflammation in mice lacking interleukin 10 by deletion of the serotonin reuptake transporter. Neurogastroenterol Motil (2010) 22(7):826-34,e229. doi:10.1111/j.1365-2982.2010.01479.x.
149. Heinsbroek SE, Gordon S. The role of macrophages in inflammatory bowel diseases. Expert Rev Mol Med (2009) 11:e14. doi:10.1017/S1462399409001069.
150. Bekiaris V, Persson EK, Agace WW. Intestinal dendritic cells in the regulation of mucosal immunity. Immunol Rev (2014) 260(1):86-101. doi:10.1111/imr.12194.
151. Dewit D, Gourlet P, Amraoui Z, Vertongen P, Willems F, Robberecht P, et al. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol Lett (1998) 60(1):57-60. doi:10.1016/S0165-2478(97)00129-6.
152. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol (1999) 96(2):167-81. doi:10.1016/S0165-5728(99)00023-5.
153. Larocca L, Calafat M, Roca V, Franchi AM, Leirós CP. VIP limits LPS-induced nitric oxide production through IL-10 in NOD mice macrophages. Int Immunopharmacol (2007) 7(10):1343-9. doi:10.1016/j.intimp.2007.05.017.
154. Xin Z, Sriram S. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J Neuroimmunol (1998) 89(1-2):206-12. doi:10.1016/S0165-5728(98)00140-4.
155. Martinez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, et al. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J Neuroimmunol (1998) 85(2):155-67. doi:10.1016/S0165-5728(98)00018-6.
156. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology (2003) 124(4):961-71. doi:10.1053/gast.2003.50141.
157. Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, García-Gómez M, et al. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis (2005) 11(7):674-84. doi:10.1097/01.MIB.0000171872.70738.58.
158. Newman R, Cuan N, Hampartzoumian T, Connor SJ, Lloyd AR, Grimm MC. Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin Exp Immunol (2005) 139(3):411-20. doi:10.1111/j.1365-2249.2005.02673.x.
159. Vu JP, Million M, Larauche M, Luong L, Norris J, Waschek JA, et al. Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice. J Mol Neurosci (2014) 52(1):37-47. doi:10.1007/s12031-013-0205-3.
160. Bannon AW, Seda J, Carmouche M, Francis JM, Norman MH, Karbon B, et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res (2000) 868(1):79-87. doi:10.1016/S0006-8993(00)02285-X.
161. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature (2008) 452(7190):997-1001. doi:10.1038/nature06858.
162. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (1996) 381(6581):415-21. doi:10.1038/381415a0.
163. Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides (2012) 46(6):261-74. doi:10.1016/j.npep.2012.08.005.
164. Sheikh SP. Neuropeptide Y and peptide YY: major modulators of gastrointestinal blood flow and function. Am J Physiol (1991) 261(5 Pt 1):G701-15.
165. Saurer TB, Ijames SG, Lysle DT. Neuropeptide Y Y1 receptors mediate morphine-induced reductions of natural killer cell activity. J Neuroimmunol (2006) 177(1-2):18-26. doi:10.1016/j.jneuroim.2006.05.002.
166. Medina S, Del Río M, Hernanz A, De la Fuente M. Age-related changes in the neuropeptide Y effects on murine lymphoproliferation and interleukin-2 production. Peptides (2000) 21(9):1403-9. doi:10.1016/S0196-9781(00)00284-9.
167. Bedoui S, Kawamura N, Straub RH, Pabst R, Yamamura T, von Hörsten S. Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol (2003) 134(1-2):1-11. doi:10.1016/S0165-5728(02)00424-1.
168. Hafström I, Ringertz B, Lundeberg T, Palmblad J. The effect of endothelin, neuropeptide Y, calcitonin gene-related peptide and substance P on neutrophil functions. Acta Physiol Scand (1993) 148(3):341-6. doi:10.1111/j.1748-1716.1993.tb09565.x.
169. Bedoui S, Kromer A, Gebhardt T, Jacobs R, Raber K, Dimitrijevic M, et al. Neuropeptide Y receptor-specifically modulates human neutrophil function. J Neuroimmunol (2008) 195(1-2):88-95. doi:10.1016/j.jneuroim.2008.01.012.
170. Singer K, Morris DL, Oatmen KE, Wang T, DelProposto J, Mergian T, et al. Neuropeptide Y is produced by adipose tissue macrophages and regulates obesity-induced inflammation. PLoS One (2013) 8(3):e57929. doi:10.1371/journal.pone.0057929.
171. Pang XH, Li TK, Xie Q, He FQ, Cui de J, Chen YQ, et al. Amelioration of dextran sulfate sodium-induced colitis by neuropeptide Y antisense oligodeoxynucleotide. Int J Colorectal Dis (2010) 25(9):1047-53. doi:10.1007/s00384-010-0964-z.
172. Chandrasekharan B, Jeppsson S, Pienkowski S, Belsham DD, Sitaraman SV, Merlin D, et al. Tumor necrosis factor-neuropeptide Y cross talk regulates inflammation, epithelial barrier functions, and colonic motility. Inflamm Bowel Dis (2013) 19(12):2535-46. doi:10.1097/01.MIB.0000437042.59208.9f.
173. Assas BM, Pennock JI, Miyan JA. Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis. Front Neurosci (2014) 8:23. doi:10.3389/fnins.2014.00023.
174. Fargeas MJ, Fioramonti J, Bueno L. Calcitonin gene-related peptide: brain and spinal action on intestinal motility. Peptides (1985) 6(6):1167-71. doi:10.1016/0196-9781(85)90445-0.
175. Rekik M, Delvaux M, Frexinos J, Bueno L. The calcitonin gene-related peptide activates both cAMP and NO pathways to induce relaxation of circular smooth muscle cells of guinea-pig ileum. Peptides (1997) 18(10):1517-22. doi:10.1016/S0196-9781(97)00246-5.
176. Szitter I, Pozsgai G, Sandor K, Elekes K, Kemeny A, Perkecz A, et al. The role of transient receptor potential vanilloid 1 (TRPV1) receptors in dextran sulfate-induced colitis in mice. J Mol Neurosci (2010) 42(1):80-8. doi:10.1007/s12031-010-9366-5.
177. Evangelista S, Tramontana M. Involvement of calcitonin gene-related peptide in rat experimental colitis. J Physiol Paris (1993) 87(4):277-80. doi:10.1016/0928-4257(93)90017-N.
178. Renzi D, Mantellini P, Calabro A, Panerai C, Amorosi A, Paladini I, et al. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis. Ital J Gastroenterol Hepatol (1998) 30(1):62-70.
179. Chang MM, Leeman SE. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem (1970) 245(18):4784-90.
180. Weinstock JV, Blum A, Metwali A, Elliott D, Arsenescu R. IL-18 and IL-12 signal through the NF-kappa B pathway to induce NK-1R expression on T cells. J Immunol (2003) 170(10):5003-7. doi:10.4049/jimmunol.170.10.5003.
181. Simeonidis S, Castagliuolo I, Pan A, Liu J, Wang CC, Mykoniatis A, et al. Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter. Proc Natl Acad Sci U S A (2003) 100(5):2957-62. doi:10.1073/pnas.0530112100.
182. Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J Immunol (2000) 165(10):5606-11. doi:10.4049/jimmunol.165.10.5606.
183. Derocq JM, Ségui M, Blazy C, Emonds-Alt X, Le Fur G, Brelire JC, et al. Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists. FEBS Lett (1996) 399(3):321-5. doi:10.1016/S0014-5793(96)01346-4.
184. Castagliuolo I, Valenick L, Liu J, Pothoulakis C. Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem (2000) 275(34):26545-50. doi:10.1074/jbc. M003990200.
185. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology (1996) 111(6):1683-99. doi:10.1016/S0016-5085(96)70034-3.
186. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis (2007) 13(7):918-32. doi:10.1002/ibd.20129.
187. Podolsky DK. Inflammatory bowel disease (1). N Engl J Med (1991) 325(13):928-37. doi:10.1056/NEJM199110033251406.
188. Liu M, Geddis MS, Wen Y, Setlik W, Gershon MD. Expression and function of 5-HT4 receptors in the mouse enteric nervous system. Am J Physiol Gastrointest Liver Physiol (2005) 289(6):G1148-63. doi:10.1152/ajpgi.00245.2005.
189. Kim JJ, Khan WI. 5-HT7 receptor signaling: improved therapeutic strategy in gut disorders. Front Behav Neurosci (2014) 8:396. doi:10.3389/fnbeh.2014.00396.
190. Margolis KG, Stevanovic K, Li Z, Yang QM, Oravecz T, Zambrowicz B, et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut (2014) 63(6):928-37. doi:10.1136/gutjnl-2013-304901.
191. Li N, Ghia JE, Wang H, McClemens J, Cote F, Suehiro Y, et al. Serotonin activates dendritic cell function in the context of gut inflammation. Am J Pathol (2011) 178(2):662-71. doi:10.1016/j.ajpath.2010.10.028.